Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Hepatology

Validation & Orientation: Understanding Hepatitis Delta (HDV)

At a Glance

Hepatitis Delta (HDV) is a satellite virus that only infects individuals who already have Hepatitis B. While it can cause faster liver damage, regular monitoring and promising new treatments like entry inhibitors offer effective ways to manage the condition and protect your liver.

Receiving a diagnosis of Hepatitis Delta (HDV) is a significant moment, especially when you are already managing Hepatitis B (HBV). It is natural to feel anxious when hearing it described as a “dual infection” or a severe form of viral hepatitis [1][2]. However, understanding the nature of this virus and the significant progress being made in modern medicine can help you build a focused plan for your health.

The “Satellite” Virus: Why HDV Needs HBV

To understand HDV, it helps to think of it as a satellite virus—a type of virus that is incomplete on its own [1]. HDV cannot infect you or reproduce unless the Hepatitis B virus is also present [3].

The Hepatitis B virus produces a “shell” called the surface antigen (HBsAg) [3]. HDV effectively “hijacks” this shell to package itself and move from cell to cell [4]. Because HDV is so dependent on its host virus, managing your Hepatitis B is a critical part of managing Hepatitis D [5].

Two Ways the Infection Happens

Doctors generally categorize HDV into two types based on when you were exposed to the viruses. Knowing which one you have helps your care team predict how the virus might behave:

  1. Co-infection: This occurs when a person is infected with both HBV and HDV at the same time [1]. While this can cause a severe initial (acute) illness, it often clears up on its own, and fewer than 5% of adults develop a long-term, chronic infection [1].
  2. Super-infection: This happens when someone who already has chronic Hepatitis B becomes infected with HDV later [1]. This is more common and more likely to lead to chronic Hepatitis Delta, which can cause faster liver damage if not monitored closely [2][6].

Stabilizing Facts for the Newly Diagnosed

While HDV is a serious condition, several facts offer a more balanced perspective on your diagnosis:

  • You Are Not Alone in Screening: Medical guidelines now recommend universal screening, meaning every person with Hepatitis B should be tested for HDV at least once, regardless of their perceived risk [7][8]. This push for testing is designed to catch the virus early when it is most manageable [9].
  • Rapid Progress in Treatment: For a long time, treatment options were limited. Today, we have entered a new era of “entry inhibitors” (like Bulevirtide) and other drugs that specifically block the virus from entering or leaving liver cells [10][11][12].
  • Proactive Monitoring Saves Lives: Even though HDV can accelerate liver disease, regular monitoring of your viral load (the amount of virus in your blood) and fibrosis (liver scarring) allows your doctor to intervene before serious damage occurs [8][13].

The Prevalence of HDV

Globally, it is estimated that about 4.5% to 5% of people with chronic Hepatitis B are also infected with HDV, though this number can be notably higher in specific regions of Africa, Asia, and Eastern Europe [13][14]. Because it was historically underdiagnosed, the medical community is now using reflex testing—automatically testing for HDV whenever HBV is found—to ensure no patient is left behind [9][15].

A Path Toward Hope

The reputation of HDV as a severe form of hepatitis stems from its ability to cause liver scarring (cirrhosis) faster than other viruses [6]. However, this severity is exactly why researchers have prioritized it. New combination therapies—pairing emerging drugs with established treatments—are showing promise in reducing the virus to undetectable levels and improving liver function [16][17]. Your diagnosis is the first step in accessing these modern tools and taking control of your long-term health.

Common questions in this guide

How is Hepatitis Delta different from Hepatitis B?
Hepatitis Delta is a 'satellite virus' that cannot survive or multiply on its own. It relies on the Hepatitis B virus, specifically hijacking its surface antigen shell, to infect liver cells. You can only contract Hepatitis Delta if you already have Hepatitis B.
What is the difference between an HDV co-infection and a super-infection?
A co-infection occurs when you contract both Hepatitis B and Hepatitis Delta at the same time, which often clears up on its own. A super-infection happens when you already have chronic Hepatitis B and later catch Hepatitis Delta, which is much more likely to become a long-term chronic illness.
Are there treatments available for Hepatitis Delta?
Yes, there has been rapid progress in treating HDV. Doctors now use new medications called entry inhibitors, such as Bulevirtide, which block the virus from entering or leaving your liver cells. These therapies are showing great promise in lowering viral levels and improving liver function.
Why does Hepatitis Delta cause more severe liver damage?
Hepatitis Delta requires careful monitoring because it can lead to liver scarring (cirrhosis) much faster than other types of hepatitis. By regularly checking your viral load and liver enzymes, your doctor can start treatment early and intervene before severe damage occurs.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my tests, do I have a co-infection or a super-infection, and what does that mean for my prognosis?
  2. 2.What is my current HDV RNA (viral load) and HBsAg level?
  3. 3.How much liver damage (fibrosis) do I currently have, and how was this measured?
  4. 4.Which of the emerging treatments might be appropriate for me?
  5. 5.Are there any clinical trials for HDV available in our area or through this health system?
  6. 6.How often will we be monitoring my liver enzymes and viral levels moving forward?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus.

    Usai C, Gill US, Riddell AC, et al.

    Alimentary pharmacology & therapeutics 2022; (55(8)):978-993 doi:10.1111/apt.16807.

    PMID: 35292991
  2. 2

    Hepatitis Delta Virus Antigens Trigger Oxidative Stress, Activate Antioxidant Nrf2/ARE Pathway, and Induce Unfolded Protein Response.

    Smirnova OA, Ivanova ON, Mukhtarov F, et al.

    Antioxidants (Basel, Switzerland) 2023; (12(4)) doi:10.3390/antiox12040974.

    PMID: 37107349
  3. 3

    Assembly and infection efficacy of hepatitis B virus surface protein exchanges in 8 hepatitis D virus genotype isolates.

    Wang W, Lempp FA, Schlund F, et al.

    Journal of hepatology 2021; (75(2)):311-323 doi:10.1016/j.jhep.2021.03.025.

    PMID: 33845061
  4. 4

    Multiple Regions Drive Hepatitis Delta Virus Proliferation and Are Therapeutic Targets.

    Zi J, Gao X, Du J, et al.

    Frontiers in microbiology 2022; (13()):838382 doi:10.3389/fmicb.2022.838382.

    PMID: 35464929
  5. 5

    Hepatitis delta virus: From infection to new therapeutic strategies.

    Niro GA, Ferro A, Cicerchia F, et al.

    World journal of gastroenterology 2021; (27(24)):3530-3542 doi:10.3748/wjg.v27.i24.3530.

    PMID: 34239267
  6. 6

    [Chronic HBV and HDV infection].

    Rusignuolo G, Thimme R, Neumann-Haefelin C

    Deutsche medizinische Wochenschrift (1946) 2024; (149(16)):948-954 doi:10.1055/a-2057-1840.

    PMID: 39094599
  7. 7

    Editorial: rapid disease progression in hepatitis delta-can we turn the tide? Authors' reply.

    Palom A, Riveiro-Barciela M, Buti M,

    Alimentary pharmacology & therapeutics 2020; (51(1)):174-175 doi:10.1111/apt.15558.

    PMID: 31850577
  8. 8

    A Review of HDV Infection.

    Caviglia GP, Ciancio A, Rizzetto M

    Viruses 2022; (14(8)) doi:10.3390/v14081749.

    PMID: 36016371
  9. 9

    Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D.

    Palom A, Rando-Segura A, Vico J, et al.

    JHEP reports : innovation in hepatology 2022; (4(10)):100547 doi:10.1016/j.jhepr.2022.100547.

    PMID: 36052219
  10. 10

    Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study.

    Jachs M, Schwarz C, Panzer M, et al.

    Alimentary pharmacology & therapeutics 2022; (56(1)):144-154 doi:10.1111/apt.16945.

    PMID: 35514008
  11. 11

    Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study.

    Rinaldi L, Viganò M, Ciancio A, et al.

    Viruses 2025; (17(2)) doi:10.3390/v17020251.

    PMID: 40007006
  12. 12

    Interferon-Free Regimens and Direct-Acting Antiviral Agents for Delta Hepatitis: Are We There Yet?

    Nemteanu R, Clim A, Hincu CE, et al.

    Current issues in molecular biology 2023; (45(10)):7878-7890 doi:10.3390/cimb45100498.

    PMID: 37886941
  13. 13

    Is hepatitis delta underestimated?

    Papatheodoridi M, Papatheodoridis GV

    Liver international : official journal of the International Association for the Study of the Liver 2021; (41 Suppl 1()):38-44 doi:10.1111/liv.14833.

    PMID: 34155795
  14. 14

    Clinical trials for Hepatitis Delta Virus in the WHO African region: A neglected virus among neglected viruses.

    Delphin M, Campbell J, Verrier ER, et al.

    The Journal of infection 2025; (91(1)):106514 doi:10.1016/j.jinf.2025.106514.

    PMID: 40409503
  15. 15

    The Forgotten Virus, Hepatitis D: A Review of Epidemiology, Diagnosis, and Current Treatment Strategies.

    Khattak A, Vongsavath T, Haque L, et al.

    Journal of clinical and experimental hepatology 2024; (14(5)):101395 doi:10.1016/j.jceh.2024.101395.

    PMID: 38617106
  16. 16

    Long-term outcome of hepatitis delta in different regions world-wide: Results of the Hepatitis Delta International Network.

    Wranke A, Lobato C, Ceausu E, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2024; (44(9)):2442-2457 doi:10.1111/liv.16006.

    PMID: 38888267
  17. 17

    Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D.

    Asselah T, Chulanov V, Lampertico P, et al.

    The New England journal of medicine 2024; (391(2)):133-143 doi:10.1056/NEJMoa2314134.

    PMID: 38842520

This page provides an overview of Hepatitis Delta for educational purposes only. Always consult your hepatologist or infectious disease specialist for professional medical advice regarding your specific HBV and HDV diagnosis.

Get notified when new evidence is published on Hepatitis delta.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.